Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pennant cuts revenue expectations after MoD contract delay

(Sharecast News) - Pennant International warned on Friday that its full-year revenue was now expected to fall below market expectations after a key Ministry of Defence contract was pushed back to 2026 or later due to new internal approval processes. In a trading update for the six months ended 30 June, the AIM-traded software and training systems company reported a sharp drop in revenue to £4.5m from £7.4m a year earlier.

Gross margins narrowed slightly to 45%, while adjusted losses before tax widened to £1.7m from £0.4m.

The group previously expected the GenFly technology upgrade contract to contribute up to 15% of full-year revenue, with an award anticipated in August.

However, Pennant now said the deal was unlikely to be finalised before the fourth quarter at the earliest.

"While it is disappointing that the GenFly contract will start later than expected, we will push to secure the award as soon as possible, while keeping focus on implementing our Auxilium strategy to achieve long-term growth in our software and services segments," said CEO Phil Walker.

"It was pleasing to see the early fruits of these efforts in the achievement of record-level annual recurring revenue during the first half."

Recurring annual revenue from the Auxilium software suite and related maintenance had grown to £2.1m, with further sales opportunities and new distribution partners expected to support growth into 2026 and beyond.

Contracted revenues for 2025 currently stood at around £9m.

Pennant said it would publish its interim results on 16 September.

At 1219 BST, shares in Pennant International were down 12.06% at 24.62p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Thalia Therapeutics enters new phase of development
(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company.
Metir inks water system deal with Portsmouth Aviation
(Sharecast News) - Metir announced Friday that it has signed a memorandum of understanding with Portsmouth Aviation to evaluate integrated water treatment and monitoring systems combining Portsmouth's PaquaVida purification platform with Metir's Modern Water Microtox biological monitoring technology.
System1 reiterates rejection of Brave Bison's revised offer
(Sharecast News) - System1 reiterated its unanimous rejection of Brave Bison's revised cash-and-share proposal on Friday, saying feedback from major shareholders supported the board's view that the offer materially undervalued the company.
ConocoPhillips to buy 42% stake in BP Iraq oil fields
(Sharecast News) - BP said on Friday that it has agreed terms for ConocoPhillips to buy a 42% interest in BP Energy Company of Kirkuk (BP ECKL).

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.